Human Parvovirus B19 Frequency Among Blood Donors After an Epidemic Outbreak: Relevance of the Epidemiological Scenario for Transfusion Medicine

Overview

Journal Heliyon

Specialty Social Sciences

Date 2020 May 13

PMID 32395652

Citations 5

Authors

Maria Pilar Adamo

Sebastian Blanco

Franco Viale

Sabrina Rivadera

Gonzalo Rodriguez-Lombardi

Mauro Pedranti

Horacio Carrizo

Sandra Gallego

Affiliations

Soon will be listed here.

Abstract

A retrospective, cross-sectional study was conducted to determine the frequency of human parvovirus B19 (B19V) infected individuals, viral loads and immunity among blood donors from Argentina, in a post-epidemic outbreak period. B19V DNA and specific IgG were tested in minimum study samples of donors attending a blood bank at Córdoba, Argentina, in 2014. Anti-B19V IgM and viral loads were determined in B19V-positive plasma samples. Seven of 731 samples (0.96%) resulted positive, corresponding to individuals aged 32-53 years, four of them repeat donnors and three first-time donors. Viral loads were <10 IU/mL. None had IgM and 6/7 had IgG, one of them at a high level (in the range of 100-200 IU/ml, and the remaining 5 at low to medium level, 5-50 IU/ml). Thus one case was classified as acute infection (DNA+/IgM-/IgG-) and six as potentially persistent infections (DNA+/IgM-/IgG+). No coinfections with other pathogens of mandatory control in the pre-transfusion screening were detected. Prevalence of IgG was 77.9% (279/358). This study provides the first data of B19V prevalence in blood donors in Argentina, demonstrating high rates of acute and persistent B19V infections and high prevalence of anti-B19V IgG in a post-epidemic period. Further research is needed to elucidate mechanisms/factors for B19V persistence as well as follow-up of recipients in the context of haemo-surveillance programs, contributing to the knowledge of B19V and blood transfusion safety.

Citing Articles

[Seroprevalence and infection by human parvovirus B19 in pregnant women from Córdoba, Argentina, 2021-2022].

Dicuatro N, Colazo Salbetti M, Boggio G, Ortiz E, Pedranti M, Olivera N Rev Fac Cien Med Univ Nac Cordoba. 2024; 81(4):670-685.

PMID: 39670897 PMC: 11905781. DOI: 10.31053/1853.0605.v81.n4.44771.

Ensuring Transfusion Safety: Screening Blood Donors for Human Parvovirus B19.

Kumari S, Kuruvilla Thomas R, R K, Barani R, Srikanth P Cureus. 2024; 16(8):e67359.

PMID: 39310657 PMC: 11413613. DOI: 10.7759/cureus.67359.

Increased parvovirus B19 seropositivity in healthy blood donors in India.

Kumari S, Kuruvilla Thomas R, Sruthi S, Barani R, Sangvi S, Krishnamoorthy R Sci Rep. 2024; 14(1):20497.

PMID: 39227628 PMC: 11372103. DOI: 10.1038/s41598-024-68095-2.

Parvovirus B19 and Parvovirus 4 infections among healthy blood donors; A prevalence report from Iran.

Sabahi M, Mosadegh M, Kazemi A, Amini R, Mahmoudvand S, Hedayat Yaghoubi M IDCases. 2024; 37:e02055.

PMID: 39220424 PMC: 11364128. DOI: 10.1016/j.idcr.2024.e02055.

Detection and analysis of parvovirus B19 among blood donors in a regional blood center in Eastern China.

Lu R, Xie S, Xu Z, Liu Z, Jiang J, Tang L Heliyon. 2024; 10(15):e35431.

PMID: 39166038 PMC: 11334868. DOI: 10.1016/j.heliyon.2024.e35431.

References

Francois K, Parboosing R, Moodley P . Parvovirus B19 in South African blood donors. J Med Virol. 2019; 91(7):1217-1223. DOI: 10.1002/jmv.25450. View

Juhl D, Gorg S, Hennig H . Persistence of Parvovirus B19 (B19V) DNA and humoral immune response in B19V-infected blood donors. Vox Sang. 2014; 107(3):226-32. DOI: 10.1111/vox.12162. View

Dorsey K, Moritz E, Steele W, Eder A, Stramer S . A comparison of human immunodeficiency virus, hepatitis C virus, hepatitis B virus, and human T-lymphotropic virus marker rates for directed versus volunteer blood donations to the American Red Cross during 2005 to 2010. Transfusion. 2012; 53(6):1250-6. DOI: 10.1111/j.1537-2995.2012.03904.x. View

Slavov S, Haddad S, Silva-Pinto A, Amarilla A, Alfonso H, Aquino V . Molecular and phylogenetic analyses of human Parvovirus B19 isolated from Brazilian patients with sickle cell disease and β-thalassemia major and healthy blood donors. J Med Virol. 2012; 84(10):1652-65. DOI: 10.1002/jmv.23358. View

Gaggero A, Rivera J, Calquin E, Larranaga C, Leon O, Diaz P . [Seroprevalence of IgG antibodies against parvovirus B19 among blood donors from Santiago, Chile]. Rev Med Chil. 2007; 135(4):443-8. DOI: 10.4067/s0034-98872007000400005. View

Juhl D, Hennig H . Parvovirus B19: What Is the Relevance in Transfusion Medicine?. Front Med (Lausanne). 2018; 5:4. PMC: 5799219. DOI: 10.3389/fmed.2018.00004. View

Slavov S, Rodrigues E, Sauvage V, Caro V, Diefenbach C, Zimmermann A . Parvovirus B19 seroprevalence, viral load, and genotype characterization in volunteer blood donors from southern Brazil. J Med Virol. 2019; 91(7):1224-1231. DOI: 10.1002/jmv.25453. View

Lee T, Kleinman S, Wen L, Montalvo L, Todd D, Wright D . Distribution of parvovirus B19 DNA in blood compartments and persistence of virus in blood donors. Transfusion. 2011; 51(9):1896-908. PMC: 3591477. DOI: 10.1111/j.1537-2995.2010.03035.x. View

Nagaharu K, Sugimoto Y, Hoshi Y, Yamaguchi T, Ito R, Matsubayashi K . Persistent symptomatic parvovirus B19 infection with severe thrombocytopenia transmitted by red blood cell transfusion containing low parvovirus B19 DNA levels. Transfusion. 2017; 57(6):1414-1418. DOI: 10.1111/trf.14088. View

10.

Tsukada Y, Yokoyama K, Ishida A, Handa M, Mori T, Kizaki M . Erythroid crisis caused by parvovirus B19 transmitted via red blood cell transfusion. Intern Med. 2011; 50(20):2379-82. DOI: 10.2169/internalmedicine.50.5458. View

11.

Zaaijer H, Koppelman M, Farrington C . Parvovirus B19 viraemia in Dutch blood donors. Epidemiol Infect. 2005; 132(6):1161-6. PMC: 2870209. DOI: 10.1017/s0950268804002730. View

12.

Kelly H, Siebert D, Hammond R, Leydon J, Kiely P, Maskill W . The age-specific prevalence of human parvovirus immunity in Victoria, Australia compared with other parts of the world. Epidemiol Infect. 2000; 124(3):449-57. PMC: 2810931. DOI: 10.1017/s0950268899003817. View

13.

Porignaux R, Vuiblet V, Barbe C, NGuyen Y, Lavaud S, Toupance O . Frequent occurrence of parvovirus B19 DNAemia in the first year after kidney transplantation. J Med Virol. 2013; 85(6):1115-21. DOI: 10.1002/jmv.23557. View

14.

Matsukura H, Shibata S, Tani Y, Shibata H, Furuta R . Persistent infection by human parvovirus B19 in qualified blood donors. Transfusion. 2008; 48(5):1036-7. DOI: 10.1111/j.1537-2995.2008.01704.x. View

15.

Pyoria L, Toppinen M, Mantyla E, Hedman L, Aaltonen L, Vihinen-Ranta M . Extinct type of human parvovirus B19 persists in tonsillar B cells. Nat Commun. 2017; 8:14930. PMC: 5382274. DOI: 10.1038/ncomms14930. View

16.

Slavov S, Otaguiri K, Covas D, Kashima S . Prevalence and Viral Load of Human Parvovirus B19 (B19V) Among Blood Donors in South-East Brazil. Indian J Hematol Blood Transfus. 2016; 32(Suppl 1):323-5. PMC: 4925535. DOI: 10.1007/s12288-015-0607-1. View

17.

Stramer S, Hollinger F, Katz L, Kleinman S, Metzel P, Gregory K . Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion. 2009; 49 Suppl 2:1S-29S. DOI: 10.1111/j.1537-2995.2009.02279.x. View

18.

Ivanova S, Mihneva Z, Toshev A, Kovaleva V, Andonova L, Muller C . Insights into epidemiology of human parvovirus B19 and detection of an unusual genotype 2 variant, Bulgaria, 2004 to 2013. Euro Surveill. 2016; 21(4). DOI: 10.2807/1560-7917.ES.2016.21.4.30116. View

19.

Slavov S, Kashima S, Rocha-Junior M, Oliveira L, Silva-Pinto A, Yamamoto A . Frequent human parvovirus B19 DNA occurrence and high seroprevalence in haemophilic patients from a non-metropolitan blood centre, Brazil. Transfus Med. 2014; 24(2):130-2. DOI: 10.1111/tme.12113. View

20.

Koppelman M, van Swieten P, Cuijpers H . Real-time polymerase chain reaction detection of parvovirus B19 DNA in blood donations using a commercial and an in-house assay. Transfusion. 2010; 51(6):1346-54. DOI: 10.1111/j.1537-2995.2010.02995.x. View